Skip to main content

Generics

  • Pfizer recalls 28 lots of branded, generic oral contraceptive

    NEW YORK — A possible pill mix-up has prompted Pfizer to recall more than two dozen lots of a prescription contraceptive drug, the drug maker said.

    Pfizer announced the voluntary nationwide recall of 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol) tablets and 14 additional lots of the drug's generic version. Pfizer manufactured and packaged the drugs, while Akrimax Pharmaceuticals commercialized them, and they were sold under the Akrimax brand.

  • FDA approves Hi-Tech Pharmacal's anxiety drug

    AMITYVILLE, N.Y. — The Food and Drug Administration has approved a generic drug for anxiety made by Hi-Tech Pharmacal, the drug maker said Tuesday.

    The FDA approved Hi-Tech's lorazepam oral concentrate in the 2-mg-per-mL strength, a generic version of Roxanne Labs' Intensol.

    Branded and generic versions of the drug had sales of $10 million in 2011, according to IMS Health.


    Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

  • PDUFA reauthorization goals draw support from NACDS

    ALEXANDRIA, Va. — A goal to standardize risk evaluation and mitigation strategies and modernize the U.S. drug safety system in a proposed reauthorization of the Prescription Drug User Fee Act has drawn support from the country's main chain retail pharmacy lobby.

    The National Association of Chain Drug Stores submitted written testimony Tuesday ahead of a congressional hearing on the reauthorization of PDUFA, originally enacted in 1992.

  • FDA approves Lannett obesity drug

    PHILADELPHIA — The Food and Drug Administration has approved a generic drug for obesity made by Lannett, the drug maker said Tuesday.

    Lannett announced the approval of phentermine hydrochloride capsules in the 15-mg strength.

    Various versions of the drug had sales of $11 million at average wholesale price in 2011, according to Wolters Kluwer.


    Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

  • Watson to open global R&D technology center

    PARSIPPANY, N.J. — Watson Pharmaceuticals is planning to open a global research and development technology center.

    The center will be a 32,000-sq.-ft., 50-acre complex consisting of lab, production and office space. The drug maker said it primarily will be used for developing generic pharmaceutical products, in particular for inhalation technology and respiratory products, with the ability to conduct formulation development and analytical testing.

  • Lannett receives FDA approval for generic Microzide

    PHILADELPHIA — Lannett announced that it has received approval from the Food and Drug Administration to market its version of a hypertension treatment.

    The drug maker said its abbreviated new drug application for hydrochlorothiazide capsules in the 12.5-mg strength was approved. The drug is a generic version of Watson Pharmaceuticals' Microzide capsules.

  • Watson, Mallinckrodt settle over generic painkiller

    PARSIPPANY, N.J. — Watson Pharmaceuticals and Mallinckrodt have reached a settlement concerning a painkiller for which the former had sought Food and Drug Administration approval.

  • Federal court clears way for Watson, Amphastar to launch generic version of Lovenox

    PARSIPPANY, N.J. — A federal court has stopped an injunction that would have prevented drug maker Watson Pharmaceuticals and partner company Amphastar Pharmaceuticals from marketing or selling a generic version of a blood-thinning drug.

X
This ad will auto-close in 10 seconds